The Prevalence and Risk Factors for Lung Atelectasis in Patients With Critical Trauma Who Are Intubated and Mechanically Ventilated

Khon Kaen University1 site in 1 country338 target enrollmentApril 2016

ConditionsPulmonary Atelectasis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pulmonary Atelectasis
Sponsor: Khon Kaen University
Enrollment: 338
Locations: 1
Primary Endpoint: number of participants with pulmonary atelectasis
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to identify the prevalence rate and risk factors for pulmonary complications in patients with critical trauma who intubated and mechanical ventilation.

Registry

clinicaltrials.gov

Start Date

April 2016

End Date

May 2017

Last Updated

8 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Khon Kaen University

Responsible Party

Principal Investigator

Guntaragorn Hongrattana

Principal Investigator

Khon Kaen University

Eligibility Criteria

Inclusion Criteria

•An inclusion criterion is the traumatic patients (e.g. head injury, blunt chest, blunt abdomen, and fracture of spine; with or without operative, pure or multitrauma) with intubation and mechanical ventilation who admit at this time period will recruit to the study.

Exclusion Criteria

•a patients who admit less than 1 day will be excluded such as sudden death or moving to other ward because of improving conditions, etc.

Outcomes

Primary Outcomes

number of participants with pulmonary atelectasis

Time Frame: from the date of randomization until the date of first documented of atelectasis, assessed up to 1 years

Secondary Outcomes

number of participants with pneumonia(from the date of randomization until the date of first documented of pneumonia, assessed up to 1 years)
number of participants with pleural effusion(from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years)
number of participants with adverse events that are related to treatment(from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years)
number of participants with abnormal laboratory values(from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years)